Sarcopenia in Patients with Advanced Gastrointestinal Well-Differentiated Neuroendocrine Tumors
Nutrients,
Journal Year:
2024,
Volume and Issue:
16(14), P. 2224 - 2224
Published: July 11, 2024
Background:
Neuroendocrine
neoplasms
(NENs)
are
slow-growing
tumors.
Sarcopenia
is
defined
as
the
loss
of
muscle
mass,
strength,
and
physical
performance.
First-line
NEN
therapy
somatostatin
analogs,
which
could
be
responsible
for
malabsorption
conditions,
such
pancreatic
exocrine
insufficiency
(EPI)
with
underlying
sarcopenia.
Aim:
Evaluate
prevalence
sarcopenia
in
patients
NENs
at
diagnosis
during
follow-up.
Methods:
A
retrospective
single-center
study
was
conducted,
including
advanced
intestinal
G1/G2
(excluded
NENs).
CT
scans
were
analyzed
after
6
months
therapy,
skeletal
index
assessed.
Results:
total
30
(F:M
=
6:24)
enrolled,
following
primary
tumor
sites:
25
ileum,
1
stomach,
2
jejunum,
duodenum.
At
diagnosis,
20
(66.6%)
showed
sarcopenic
SMI
values,
10
(33.3%)
non-sarcopenic
values.
follow-up,
three
more
developed
Statistical
significance
relation
to
presence
found
group
carcinoid
syndrome
(p
0.0178),
EPI
0.0018),
weight
0.0001).
Conclusion:
present
2/3
It
reasonable
consider
this
condition
improve
clinical
outcomes.
Language: Английский
Gastroenteropancreatic neuroendocrine neoplasms: epidemiology, genetics, and treatment
Baizhou Tan,
No information about this author
Beiyu Zhang,
No information about this author
Hongping Chen
No information about this author
et al.
Frontiers in Endocrinology,
Journal Year:
2024,
Volume and Issue:
15
Published: Sept. 30, 2024
The
incidence
of
gastroenteropancreatic
neuroendocrine
neoplasms
(GEP
NEN)
is
increasing
at
a
rapid
pace
and
becoming
an
increasingly
important
consideration
in
clinical
care.
Epidemiological
data
from
multiple
countries
indicate
that
the
exhibits
regional,
site-specific,
gender-based
variations.
While
genetics
pathogenesis
some
GEP
NEN,
particularly
pancreatic
NENs,
have
been
investigated,
there
are
still
many
mechanisms
require
further
investigation.
management
NEN
diverse,
but
surgery
remains
primary
option
for
most
cases.
Peptide
receptor
radionuclide
therapy
(PRRT)
effective
treatment,
several
trials
exploring
potential
immunotherapy
targeted
therapy,
as
well
combination
therapy.
Language: Английский
The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives
E Lauricella,
No information about this author
Sofija Vilisova,
No information about this author
Nada Chaoul
No information about this author
et al.
Expert Review of Neurotherapeutics,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 14
Published: Oct. 16, 2024
Somatostatin
analogs
(SSAs)
were
developed
as
antisecretory
agents
to
palliate
hormonal
symptoms
in
patients
with
functioning
neuroendocrine
tumors
(NETs).
Their
antiproliferative
activity
has
been
established
the
phase
3
PROMID
and
CLARINET
trials.
SSAs
currently
represent
standard
first-line
therapy
for
majority
of
well-differentiated
G1/G2
gastroenteropancreatic
NETs
well
pulmonary
NETs.
Language: Английский
Exploring Carcinoid Syndrome in Neuroendocrine Tumors: Insights from a Multidisciplinary Narrative Review
Cancers,
Journal Year:
2024,
Volume and Issue:
16(22), P. 3831 - 3831
Published: Nov. 14, 2024
Carcinoid
syndrome
(CS)
is
a
rare
condition
associated
with
neuroendocrine
tumors
(NETs),
particularly
those
originating
in
the
gastrointestinal
tract,
which
secrete
bioactive
substances
like
serotonin.
The
management
of
CS
requires
multidisciplinary
approach
due
to
its
complex
clinical
manifestations,
including
flushing,
diarrhea,
bronchospasm,
and
carcinoid
heart
disease.
Optimal
care
involves
collaboration
between
several
professional
figures
oncologists,
endocrinologists,
gastroenterologists,
surgeons,
dietitians.
Currently,
wide
range
treatments
are
available,
focused
on
both
symptom
control
tumor
burden
reduction.
Somatostatin
analogs
(SSAs)
first-line
therapy
for
relief.
Still,
patients
progressive
disease
or
refractory
CS,
other
options
include
targeted
therapies,
peptide
receptor
radionuclide
(PRRT),
liver-directed
surgical
resection,
when
feasible.
Furthermore,
complications
related
prolonged
serotonin
release
malnutrition
as
result
exocrine
pancreatic
insufficiency,
post-surgical
conditions,
vitamin
deficit,
chronic
diarrhea
often
early
detection
mitigate
symptoms
improve
quality
life
these
patients.
complexity
necessitates
individualized
continuous
coordination
among
specialists
optimize
outcomes
enhance
patient
well-being.
Language: Английский
miRNA Expression Profiling in G1 and G2 Pancreatic Neuroendocrine Tumors
Cancers,
Journal Year:
2024,
Volume and Issue:
16(14), P. 2528 - 2528
Published: July 13, 2024
Pancreatic
neuroendocrine
neoplasms
pose
a
growing
clinical
challenge
due
to
their
rising
incidence
and
variable
prognosis.
The
current
study
aims
investigate
microRNAs
(miRNA;
miR)
as
potential
biomarkers
for
distinguishing
between
grade
1
(G1)
2
(G2)
pancreatic
tumors
(PanNET).
A
total
of
33
formalin-fixed,
paraffin-embedded
samples
were
analyzed,
comprising
17
G1
16
G2
tumors.
Initially,
literature-based
miRNAs
validated
via
real-time
quantitative
reverse
transcription
polymerase
chain
reaction
(RT-qPCR),
confirming
significant
downregulation
Language: Английский